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Abstract: 
Beta-lapachone (beta-Lp) derived from the Lapacho tree is a potentially novel anticancer agent 
currently under clinical trials. Previous studies suggested that redox activation of beta-Lp 
catalyzed by NAD(P)H:quinone oxidoreductase 1 (NQO1) accounted for its killing of cancer 
cells. However, the exact mechanisms of this effect remain largely unknown. Using 
chemiluminescence and electron paramagnetic resonance (EPR) spin-trapping techniques, this 
study for the first time demonstrated the real-time formation of ROS in the redox activation of 
beta-lapachone from cancer cells mediated by mitochondria and NQO1 in melanoma B16–F10 
and hepatocellular carcinoma HepG2 cancer cells. ES936, a highly selective NQO1 inhibitor, 
and rotenone, a selective inhibitor of mitochondrial electron transport chain (METC) complex I 
were found to significantly block beta-Lp meditated redox activation in B16–F10 cells. In 
HepG2 cells ES936 inhibited beta-Lp-mediated oxygen radical formation by ~ 80% while 
rotenone exerted no significant effect. These results revealed the differential contribution of 
METC and NQO1 to beta-lapachone-induced ROS formation and cancer cell killing. In 
melanoma B16–F10 cells that do not express high NQO1 activity, both NOQ1 and METC play a 
critical role in beta-Lp redox activation. In contrast, in hepatocellular carcinoma HepG2 cells 
expressing extremely high NQO1 activity, redox activation of beta-Lp is primarily mediated by 
NQO1 (METC plays a minor role). These findings will contribute to our understanding of how 
cancer cells are selectively killed by beta-lapachone and increase our ability to devise strategies 
to enhance the anticancer efficacy of this potentially novel drug while minimizing its possible 
adverse effects on normal cells. 
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Introduction 
 
Cancer is one of the major causes of death worldwide. Currently, there is no cure for the large 
majority of cancers, and as such, development of effective anticancer drugs is of urgent clinical 
importance. In this context, beta-lapachone (beta-Lp), a quinone compound derived from 
Lapacho tree, has been shown to be highly effective in treating various types of cancer in 
experimental models, including liver cancer and melanoma (Blanco et al., 2010, Brightman et 
al., 1992, Dong et al., 2009, Pardee et al., 2002 and Reinicke et al., 2005). This novel agent is 
also currently under clinical trials for treating cancer patients (Trachootham et al., 2009). 
Although beta-Lp is a promising anticancer agent, its mechanisms of action still need to be fully 
elucidated. The leading theory holds that beta-Lp reacts with the cellular enzyme 
NAD(P)H:quinone oxidoreductase 1 (NQO1), which is overexpressed in many cancers, leading 
to a futile cycling between its quinone and hydroquinone forms, thereby consuming NADPH and 
generating reactive oxygen species (ROS) (Pink et al., 2000 and Siegel et al., 2012). It is 
suggested that depletion of NADPH may trigger cancer cell apoptosis. In addition, formation of 
ROS from redox cycling of beta-Lp may also contribute to its cancer cell killing activity (Pink et 
al., 2000 and Siegel et al., 2012). Also, current theories seem to agree on the importance of 
NQO1 in the anticancer action of beta-Lp, especially in cancer cells that express high NQO1 
activity (Pink et al., 2000 and Siegel et al., 2012). In most of the experiments verifying NQO1 as 
the principal cellular factor, the NQO1 inhibitor dicumarol was used (Bey et al., 2007, Li et al., 
2011 and Pardee et al., 2002). Dicumarol, however, is also a mitochondrial inhibitor (Gonzalez-
Aragon et al., 2007), making it difficult to delineate the exact role of NQO1 in redox activation 
of beta-Lp. Moreover, the involvement of other cellular factors in redox activation of beta-Lp in 
cancer cells that do not express high NQO1 activity and the subsequent real-time formation of 
ROS remain unknown. Unlike those in normal cells, mitochondria in cancer cells are extremely 
inefficient in generating ATP, which provides energy for cellular work, in part because of 
excessive electron leakage in the electron transport chain (Enns and Ladiges, 2012 and Lu et al., 
2012). We hypothesized that leaked electrons from mitochondrial electron transport chain 
(METC) may also play a role in redox activation of beta-Lp and thus the generation of ROS, 
particularly in cancer cells that do not express high NQO1 activity. Using melanoma and 
hepatocellular carcinoma cell lines and selective NQO1 and mitochondrial inhibitors as well as 
purified NQO1 enzyme and isolated mitochondria, we for the first time demonstrated real-time 
formation of ROS from cancer cell mitochondria- and NQO1-mediated redox activation of beta-
Lp and revealed the differential contribution of METC and NQO1 to beta-Lp-induced ROS 
formation and cancer cell killing. These findings may significantly contribute to our 
understanding of how beta-Lp becomes redox activated to selectively kill cancer cells and may 
thus increase our ability to develop strategies to enhance its cancer killing activity while 
minimizing its potential adverse effects on normal cells. 
Materials and methods 
Materials 
B16–F10 melanoma and hepatocellular carcinoma HepG2 cell lines were from ATCC 
(Manassas, VA). Dulbecco's modified Eagle's medium (DMEM), penicillin, streptomycin, fetal 
bovine serum (FBS), and phosphate-buffered saline (PBS) were from Invitrogen (Carlsbad, CA). 
Cell culture flasks and other plastic wares were from Corning (Corning, NY). The specific 
NQO1 inhibitor ES936 was a gift from Dr. David Ross (University of Colorado, Denver). The 
spin traps 5-(Diethoxyphosphoryl)-5-methyl-1-pyrroline-N-oxide (DEPMPO) and 5,5-dimethyl-
1-pyrroline N-oxide (DMPO) were from Enzo (Farmingdale, NY). Recombinant human NQO1 
was from MyBioSource (San Diego, CA). All other chemicals/agents were from Sigma (St. 
Louis, MO). 
Cell culture 
B16–F10 and HepG2 cells were cultured in DMEM supplemented with 10% FBS, 100 U/ml 
penicillin and 100 μg/ml streptomycin at 37 °C in a humidified atmosphere of 5% CO2. 
Isolation of mitochondria 
Mitochondria were isolated from freshly harvested B16–F10 cells by differential centrifugation 
method described before (Zhu et al., 2009). Briefly, cells were washed once with PBS and 
centrifuged. The cell pellet was resuspended in 5 ml sucrose buffer (0.25 M sucrose, 10 mM 
Hepes, 1 mM EGTA and 0.5% BSA, pH 7.4), homogenized in a Dounce tissue grinder on ice. 
The homogenate was centrifuged at 1500 g for 10 min at 4 °C. The supernatant was collected 
and centrifuged at 10,000 g for 10 min at 4 °C. The resulting mitochondrial pellet was washed 
twice with sucrose buffer and then resuspended in ice-cold 50 mM potassium phosphate buffer, 
pH 7.0, containing 1 mM EDTA and 0.1% Triton X-100, followed by sonication to lyse the 
mitochondria. The resulting mitochondrial pellet was washed twice with sucrose buffer and kept 
on ice for ROS measurement (see below). 
NQO1 activity assay 
Cellular NQO1 activity was determined using dichloroindophenol (DCIP) as the two-electron 
acceptor, as described before (Zhu et al., 2009). The dicumarol-inhibitable cellular NQO1 
activity was calculated using the extinction coefficient of 21.0 mM− 1 cm− 1, and expressed as 
nanomoles of DCIP reduced per minute per milligram of cellular protein. 
Oxygen consumption assay 
The rate of O2 consumption by cancer cells was measured polarographically with a Clark-type 
O2 electrode at 37 °C in 2.5 ml complete PBS, as described before (Li and Trush, 1998). For 
measuring O2 consumption stimulated by beta-Lp redox cycle, 0.2 mM KCN was added to 
inhibit mitochondrial respiration before adding beta-Lp to the cell suspension. 
Chemiluminescence (CL) assays 
Chemiluminescence (CL) assays are best known for their remarkable sensitivity in detecting 
cellular ROS in various biological systems as previously described by us and others (Li and 
Trush, 1998, Li et al., 1998, Li et al., 1999a and Li et al., 1999b). In this context, lucigenin-
amplified CL assay has been used to sensitively detect biological superoxide generation. On the 
other hand, luminol-amplified CL in the present of horseradish peroxidase (HRP) has been used 
to sensitively detect H2O2 formation in cells and isolated mitochondria (Li and Trush, 1998, Li et 
al., 1998, Li et al., 1999a and Li et al., 1999b). For detecting cellular ROS formation, CL was 
continuously measured with a Berthold LB9505 luminometer at 37 °C upon mixing the cells 
(1 × 106/ml) with lucigenin (20 μM) or luminol (10 μM) plus HRP (10 μg/ml) in complete PBS. 
For measuring mitochondrial H2O2 release, CL was measured in the same manner as described 
above upon mixing mitochondria (0.05 mg/ml) with 0.5 mM pyruvate and 0.5 mM malate (to 
provide NADH for the mitochondrial electron transport chain) in respiration buffer. 
Electron paramagnetic resonance (EPR) assay 
For spin-trapping measurement of oxygen radicals, EPR spectra were recorded at room 
temperature with a spectrometer (E-Scan, Bruker), operating at X-band with a TM cavity, as 
described previously (Zang and Misra, 1993). For measuring cellular oxygen radical formation, 
cells (1 × 106/ml) containing 10 μM Fe2 + in complete PBS were incubated with 80 mM DMPO 
in the presence or absence of beta-Lp at 37 °C for 5 min before being subject to EPR 
measurement. The EPR spectrometer settings of DMPO spin trapping measurement were: 
modulation frequency, 100 kHz; X-band microwave frequency, 9.5 GHz; microwave power, 
15 mW (milliwatts); modulation amplitude, 1.0 G (gauss); time constant, 160 s; scan time, 200 s; 
and receiver gain, 1 × l05. For measuring oxygen radical formation by isolated mitochondria, 
mitochondria (0.05 mg/ml) were incubated with 25 mM DEPMPO in respiration buffer in the 
presence or absence of beta-Lp at 37 °C for 5 min before being subject to EPR measurement. For 
measuring oxygen radical formation from purified NQO1-catalyzed redox cycling of beta-Lp, 
NQO1 (0.5 μg/ml) was incubated with 0.25 mM NADPH and 25 mM DEPMPO in complete 
PBS in the presence or absence of beta-Lp at 37 °C for 5 min before being subject to EPR 
measurement. The EPR spectrometer settings of DEPMPO spin trapping measurement were: 
modulation frequency, 100 kHz, X band microwave frequency, 9.5 GHz; microwave power, 
20 mW (milliwatts); modulation amplitude, 1 G (gauss); time constant, 160 s; scan time, 50s; 
and receiver gain, 5 × l05. 
Spectrophotometric assay for NADPH consumption 
Measurement of NADPH was determined using methods as described previously (Brightman et 
al., 1992). In brief, cells were first washed with DMEM medium without phenol red, pH 7.4. 
NADPH consumption was monitored continuously at 340 nm using a Beckman Coulter DU 800 
spectrophotometer for 5 min at 37 °C upon mixing NQO1 (0.5 μg/ml) with 25 mM NADPH in 
complete PBS in the presence or absence of beta-Lp. 
Cytotoxicity assay and microscopic examination 
Cell viability was determined by MTT assay as described before (Mosmann, 1983). In brief, 
cells (2 × 105cells/well in 0.5 ml culture medium) were plated into 24-well tissue culture plates. 
After incubation of the cells with beta-Lp in DMEM supplemented with 0.5% FBS at 37 °C for 
24 h, the morphological changes were examined under an inverted phase contrast microscope 
and photographed using a Nikon Digital Sight camera with NIS Elements D3 software. Then, 
50 μl of MTT (2 mg/ml PBS) was added to each well followed by 2-hr incubation at 37 °C. The 
reduction of MTT to formazan by viable cells was detected at 570 nm. Cell viability was 
expressed as percentage of MTT reduction in control cells. 
Statistical analysis 
All data are expressed as mean ± SD from at least three separate experiments unless otherwise 
indicated. Differences between the mean values of multiple groups were analyzed by one-way 
analysis of variance followed by Student–Newman–Keuls test. Differences between the 2 groups 
were analyzed by Student t-test. Statistical significance was considered at p < 0.05. 
Results and discussion 
Selection and characterization of melanoma B16–F10 and hepatocellular carcinoma HepG2 cells 
Cell culture models are crucial for understanding the biology of cancer cells as well as the action 
of anticancer drugs. In this study, mouse melanoma B16–F10 and human hepatocellular 
carcinoma HepG2 cell lines were selected because metastatic melanoma and hepatocellular 
carcinoma are among the cancers with poor prognosis and that lack effective therapies (Neuzillet 
et al., 2014, Tronnier and Mitteldorf, 2014 and Villanueva et al., 2013). In addition, B16–F10 
cells were derived from C57BL/6 mice, and the cells can be implanted into the mice to serve as a 
commonly used in vivo model for cancer research (Kayaga et al., 1999, Lentini et al., 
2012 and Shao et al., 2001). As shown in Fig. 1A, both B16–F10 and HepG2 cells exhibited 
similar mitochondrial respiration as assessed by KCN-sensitive O2 consumption. However, B16–
F10 cells showed higher mitochondrial superoxide production than HepG2 cells, as detected by 
lucigenin-derived CL (Fig. 1B), suggesting that mitochondrial electron transport chain (METC) 
in B16–F10 cells may be more leaky than that in HepG2 cells. It has been proposed that 
mitochondria in cancer cells, especially those with high metastatic potential, produce more ROS 
than those in normal cells, and the basal ROS formation may play a role in maintaining 
malignant phenotype (Enns and Ladiges, 2012, Ishii, 2007, Kamat and Devasagayam, 
2000, Ralph et al., 2010, Singh, 2006, Wallace, 2005 and Wenner, 2012). Indeed, B16–F10 cells 
are much more metastatic than HepG2 cells (Wu et al., 2009). Whether the elevated basal 
production of mitochondrial superoxide plays a role in melanoma metastasis warrants further 
investigation. Notably, although HepG2 cells showed lower basal mitochondrial superoxide 
production, these cells contained a much higher level (> 40-fold) of NQO1 than B16–F10 cells 
(Fig. 1C). The differences in mitochondrial activity and NQO1 levels in these 2 cancer cell lines 
make them useful in vitro models for studying the mechanistic roles of mitochondria and NQO1 
in redox activation of beta-Lp to lead to cancer cell killing. 
 
Fig. 1. Mitochondrial and NQO1 activities, and KCN resistant oxygen consumption in 
melanoma B16–F10 cells and hepatocellular carcinoma HepG2 cells. Panel A shows KCN-
sensitive cellular oxygen consumption indicating mitochondrial respiration; panel B shows 
mitochondrial superoxide production detected by lucigenin-derived CL (LDCL) in the cancer 
cells; lucigenin concentration is 20 μM. Panel C shows NQO1 activity as measured by 
dicumarol-inhibitable reduction of DCIP. Panels D–E show beta-Lp redox cycling as determined 
by KCN-resistant O2 consumption. Values are mean ± SEM, n = 3. *, p < 0.05 as compared with 
B16–F10 cells (panel C). *p < 0.05 compared with beta-lapachone 1 μM in B16–F10 cells (panel 
E); #p < 0.05 compared with beta-lapachone 10 μM in B16–F10 cells (panel E). 
Evidence for redox cycling of beta-Lp in cancer cells 
Although it has been claimed in the literature that beta-Lp may undergo futile redox cycling in 
cancer cell, direct evidence is still lacking. Hence, we decided to first use KCN-resistant 
O2 consumption assay to determine the redox cycling property of this compound in both B16–
F10 and HepG2 cells. KCN-resistant O2consumption is widely accepted as a gold-standard assay 
for determining chemical redox cycling. As shown in Figs. 1D–E, addition of beta-Lp to the 
cancer cells resulted in marked KCN-resistant O2 consumption, indicating that beta-Lp is a redox 
cycler in both types of cancer cells. Notably, beta-Lp stimulated more KCN-resistant 
O2 consumption in HepG2 cells than in B16–F10 cells, suggesting more potent redox activation 
of beta-Lp in HepG2 cells. This is in line with the data showing that HepG2 cells expressed a 
much higher level of NQO1 than B16–F10 cells (Fig. 1C). 
Formation of ROS from redox cycling of beta-Lp in cancer cells 
As stated in the Introduction section, redox cycling of beta-Lp may lead to depletion of NADPH 
and generation of ROS (Pink et al., 2000). However, evidence showing real-time formation of 
ROS from redox activation of beta-Lp in cancer cells is lacking. There is only one published 
article showing that beta-Lp stimulated dichlorodihydrofluoroscein (DCF) fluorescence (Park et 
al., 2011), an assay for overall oxidative stress. However, DCF assay suffers major limitations, 
including its non-specificity for ROS. In this regard, metal ions and peroxidase are able to 
oxidize DCF to form fluorescent product (Rota et al., 1999). In view of the above, we used the 
highly sensitive chemiluminescence assay and the most specific EPR spin-trapping technique to 
determine the ROS formation from beta-Lp redox activation in cancer cells. Fig. 2 showed the 
real-time formation of cellular H2O2 as detected by luminol CL in the presence of HRP. In data 
not shown, this CL response was blocked by adding catalase, proving that the CL response was 
indicative of H2O2formation. The formation of cellular H2O2 from beta-Lp redox activation was 
concentration-dependent in both types of cancer cells. Notably, the kinetics of H2O2 formation in 
HepG2 cells was much faster than that in B16–F10 cells (Figs. 2A, B). Integrated CL which is 
indicative of the total amounts of H2O2 formed over 30 min showed that beta-Lp produced more 
H2O2 in HepG2 cells than in B16–F10 cells (Figs. 2C, D). This observation was in agreement 
with the data shown earlier (Fig. 1) that redox cycling of beta-Lp occurred more rigorously in 
HepG2 cells than in B16–F10 cells. The more rapid kinetics and higher amounts of 
H2O2formation in HepG2 cells were also in line with the data showing that HepG2 cells 
expressed 40-fold higher NQO1 activity than B16–F10 cells (Fig. 1C). 
 
Fig. 2. Real-time and accumulated formation of reactive oxygen species (ROS) from beta-Lp 
redox activation in cancer cells detected by luminol/HRP-dependent CL and EPR. Real time 
formation of ROS from beta-lapachone redox cycling was detected by time-dependent luminol 
CL in the presence of HRP in melanoma B16–F10 cells (panel A) and hepatocellular carcinoma 
HepG2 cells (panel B). Integrated luminol CL in the presence of HRP in melanoma B16–F10 
cells (panel C) and hepatocellular carcinoma HepG2 cells (panel D) was measured in 30 min in 
the presence of HRP from beta-lapachone redox cycling. Panel E shows the formation of 
hydroxyl radicals from beta-Lp (10 μM) redox activation detected by EPR DMPO (80 mM) spin-
trapping in B16–F10 (lanes a–b) and HepG2 (lanes c–d) cells in complete PBS. In data not 
shown, the luminol/HRP-dependent CL response was completely blocked by adding catalase 
(250 U/ml), indicating that this assay under the conditions described in this study measures 
H2O2 released from the cancer cells. Values are mean ± SEM, n = 3. *, p < 0.05 versus control 
HepG2 cells. 
EPR spin-trapping was further employed to detect oxygen radical formation by beta-Lp in cancer 
cells. As shown in Fig. 2E, incubation of cancer cells with beta-Lp led to the formation of 
DMPO-OH adduct with aN = aH = 14.9 G, indicating hydroxyl radical formation. DMPO has 
been widely used as a good candidate for spin trapping agent to study the production of reactive 
free radicals such as hydroxyl radicals in biological systems (Hojo et al., 2000, Liu et al., 
1999 and Timmins et al., 1999). However, it was reported that the hydroxyl radical spin-adduct, 
DMPO-OH could also be derived from the decomposition of the superoxide spin-adduct 
(DMPO-OOH) (Hojo et al., 2000, Jia et al., 2009, Liu et al., 1999 and Timmins et al., 1999). To 
further study whether the DMPO-OH was initially derived from DEPMO-OOH, we added 
500 U/ml superoxide dismutase (SOD) prior to initiation of the reactions. In data not shown, the 
intensity of DMPO-OH spectrum was not affected by SOD indicating that the DMPO-OH signal 
is not mediated by the decomposition of the superoxide spin-adduct (DMPO-OOH), which is 
consistent with our previous report (Jia et al., 2009). Consistent with the CL data, hydroxyl 
radical formation in HepG2 cells was also more dramatic than that in B16–F10 cells. Our data 
for the first time conclusively demonstrated the real-time formation of H2O2 as well as the 
generation of hydroxyl radicals from beta-Lp redox activation in cancer cells. 
Role of mitochondrial electron transport chain (METC) and NQO1 in redox activation of beta-
Lp to produce ROS in cancer cells 
As mentioned in the Introduction section, NQO1 has been suggested to be the principal factor to 
mediate redox activation of beta-Lp in cancer cells. This conclusion was derived largely from the 
use of the non-selective NQO1 inhibitor, dicumarol, which also affects mitochondrial activity 
(Gonzalez-Aragon et al., 2007). To further investigate the exact role of cellular NQO1 in redox 
activation of beta-Lp, we used ES936, a highly selective and potent NQO1 inhibitor, which 
could completely inhibit cellular NQO1 at < 1 μM (Dehn et al., 2003). Rotenone, a selective 
inhibitor of METC complex I (Fang and Beattie, 2002, Genova et al., 1997,Li et al., 
1999b and Uyemura et al., 2004) was used to determine the involvement of METC in beta-Lp 
redox activation. As shown in Figs. 3A, B, redox activation of beta-Lp to generate 
H2O2 (detected by luminol/HRP-dependent CL) was significantly reduced by ES936, rotenone, 
and dicumarol. Interestingly, on average, ES936 and rotenone each inhibited the H2O2 formation 
by ~ 40%, and dicumarol alone inhibited the H2O2formation by ~ 80%. As shown later 
in Fig. 4C, METC-mediated redox activation by beta-Lp was also inhibited by dicumarol 
suggesting the dramatic effect of dicumarol on beta-Lp-induced H2O2 formation in B16–F10 
cells. The above data suggested that in cancer cells like B16–F10 melanoma cells that do not 
express high NQO1 activity, both NQO1 and METC seemed to play an equally important role in 
redox activation of beta-Lp to generate ROS. By comparing the effects of ES936 and rotenone 
on redox activation of beta-Lp at 2 different concentrations (i.e., 1 and 10 μM) (Figs. 3A, B), we 
found that in B16–F10 cells incubated with 1 μM beta-Lp, rotenone had an inhibitory effect of 
~ 45%, whereas ES936 had an inhibitory effect of ~ 32%. When the concentration of beta-Lp 
was increased to 10 μM, an increased inhibition by ES936 (~ 41%) and a decreased inhibition by 
rotenone (~ 32%) occurred. This suggested that at lower concentrations, mitochondria might be 
significantly involved in beta-Lp redox activation to produce ROS. At higher concentrations of 
beta-Lp, likely due to the limited capabilities of METC, NQO1 seemed to play a more significant 
role. 
 
Fig. 3. The roles of mitochondrial electron transport chain (METC) complex I and NQO1 in 
redox activation of beta-Lp to produce ROS in cancer cells. Dicumarol (10 μM), a non-selective 
NQO1 inhibitor, ES936 (1 μM), a highly selective and potent NQO1 inhibitor, and rotenone 
(10 μM), a selective inhibitor of METC complex I were used to determine the involvement of 
cellular NQO1 and METC complex I in beta-Lp redox activation in B16–F10 (panels A and B) 
and HepG2 cells (panels C and D), as detected by luminol/HRP-dependent CL. Concentrations 
of beta-lapachone are 1 μM (panels A and C) and 10 μM (panels B and D). Values are 
mean ± SEM, n = 3. *, p < 0.05 versus beta-Lp alone. 
 
Fig. 4. Detection of ROS in isolated mitochondria by real-time luminol/HRP CL and EPR as 
well as the involvement of METC/NQO1 in the beta-lapachone redox cycling. Formation of 
ROS from beta-Lp redox activation in isolated mitochondria driven by pyruvate/malate was 
measured by luminol CL. (HRP 10 μg/ml; luminol 10 μM). Panel A shows real-time luminol CL 
response; panel B shows integrated luminol CL for accumulated ROS formation over 30 min. 
Panel C shows effect of ES936, rotenone, and dicumarol on beta-lapachone induced ROS 
formation in the isolated mitochondria driven by pyruvate/malate. Panel D shows DEMPO-spin 
trapping detection of superoxide production from beta-Lp (10 μM) redox cycling in the isolated 
mitochondria driven by pyruvate/malate. DEPMPO 25 mM; beta-lapachone 10 μM; rotenone 
10 μM; ES936 1 μM; SOD 500 U/ml. 
As HepG2 cells expressed a 40-fold higher NQO1 activity than B16–F10 cells, we next 
determined the effects of ES936 as well as rotenone and dicumarol on beta-Lp redox activation 
in these cells. As shown in Figs. 3C, D, while ES936 and dicumarol each inhibited beta-Lp-
mediated H2O2 formation by ~ 80% on average, rotenone exerted no significant effect. This data 
suggested that in cancer cells like HepG2 cells expressing extremely high NQO1 activity, 
NQO1-mediated redox activation of beta-Lp seemed to be predominant, and METC appeared to 
play a very minor, if any, role in the redox activation process. 
Studies with isolated mitochondria and purified NQO1 
To further prove the involvement of METC and NQO1 in mediating redox activation of beta-Lp 
to produce ROS, we next used mitochondria isolated from B16–F10 cells and commercially 
available recombinant human NQO1 enzyme. As shown in Figs. 4A–B, the release of H2O2 by 
pyruvate/malate-driven mitochondria as detected by luminol/HRP-dependent CL was markedly 
stimulated by beta-Lp in a concentration-dependent manner. Importantly, beta-Lp-stimulated 
H2O2 formation in isolated mitochondria was dramatically inhibited (~ 60%) by rotenone as well 
as by dicumarol (~ 40% inhibition) (Fig. 4C). This data indicated that METC, especially its 
complex I was indeed capable of mediating redox activation of beta-Lp. The incomplete 
inhibition of beta-Lp redox activation by rotenone suggested the possible involvement of other 
METC complexes in mediating beta-Lp redox activation to form ROS. The marked inhibition of 
beta-Lp redox activation in isolated mitochondria by dicumarol and the inability of ES936 to do 
so confirmed that dicumarol is not a selective inhibitor of NQO1, and as such, it should not be 
used for studying the role of NQO1 in beta-Lp redox activation. On the other hand, our data 
supported the use of ES936 for such a purpose. 
In line with the H2O2 formation as detected by luminol/HRP-dependent CL, this study for the 
first time revealed that beta-Lp stimulated superoxide formation in isolated mitochondria 
(Fig. 4D). As shown in Fig. 4D, incubation of mitochondria with beta-Lp (10 μM) and DEPMPO 
(25 mM) led to the generation of a spin-adduct that was completed inhibited by superoxide 
dismutase (SOD), proving the formation of superoxide. Notably, the production of superoxide 
was completely blocked by rotenone, but not affected by ES936, again indicating that ES936 at 
1 μM did not affect METC, and that its attenuation of cellular ROS formation from beta-Lp 
redox activation in cancer cells (Fig. 3) was due to the selective inhibition of cellular NQO1. 
These results with isolated mitochondria further supported a critical role for METC in mediating 
redox activation of beta-Lp to produce ROS in melanoma B16–F10 cells. 
The experiment with purified NQO1 enzyme also proved the ability of NQO1 to catalyze redox 
activation of beta-Lp to form ROS (Fig. 5). As shown in Fig. 5A, beta-Lp potently stimulated 
NQO1-catalyzed reaction, leading to the consumption of NADPH in a cell-free system. The 
consumption of NADPH was completely inhibited by ES936, confirming that the enzymatic 
activity of NQO1 was essential for catalyzing redox activation of beta-Lp. This study also for the 
first time demonstrated the formation of oxygen radicals from purified NQO1 enzyme-catalyzed 
beta-Lp redox activation (Fig. 5B). As shown in Fig. 5B, incubation of NQO1 with 10 μM beta-
Lp in the presence of NADPH and DEPMPO led to the formation of a spin-adduct. Although the 
chemical entity of the spin-adduct remains to be determined, the formation of the spin-adduct 
was greatly inhibited by SOD, suggesting that this spin-adduct was derived largely from 
superoxide. The formation of this largely superoxide-dependent adduct was completely inhibited 
by ES936, again indicating the dependence of beta-LP redox activation on NQO1 enzymatic 
activity. Collectively, the results from the experiments with purified NQO1 enzyme proved that 
NQO1 can directly catalyze redox activation of beta-Lp to produce ROS. 
 
Fig. 5. Beta-lapachone-induced NADPH consumption and EPR detection of superoxide 
production catalyzed by isolated NQO1. Panel A: Consumption of NADPH (0.25 mM) by 
NQO1 (0.5 μg/ml) was monitored for 5 min at 340 nm in the presence or absence of Beta-Lp 
(10 μM) and ES936 (1 μM). Panel B: EPR detection of Beta-Lp (10 μM)-mediated superoxide 
production catalyzed by NQO1 (0.5 μg/ml). DEPMPO, 25 mM; SOD, 500 U/ml. 
Beta-Lp-induced cytotoxicity in cancer cells and the potential involvement of ROS, METC and 
NQO1 in mediating redox activation of beta-Lp to kill cancer cells 
The data presented in Fig. 1, Fig. 2, Fig. 3, Fig. 4 and Fig. 5 collectively showed that beta-Lp 
underwent mitochondria- and NQO1-mediated redox activation to generate large amounts of 
ROS in cancer cells. We next determined the cytotoxicity of beta-Lp in both B16–F10 and 
HepG2 cancer cells. As shown in Fig. 6, beta-Lp elicited cytotoxicity in both types of cancer 
cells in a concentration-dependent manner, as assessed by morphologic changes (cells became 
round and detached) (Fig. 6A) and MTT reduction assay (Fig. 6B). As shown in Fig. 6C, 
rotenone significantly attenuated beta-Lp cytotoxicity to B16–F10 cells, which once again 
supported the notion that METC was involved in redox activation of beta-Lp to lead to the death 
of cancer cells that do not express high NQO1 activity. Notably, beta-Lp was more cytotoxic to 
HepG2 cells than to B16–F10 cells. This observation was in line with the data showing that beta-
Lp underwent more dramatic redox activation to produce higher amounts of ROS in HepG2 cells 
than in B16–F10 cells (Fig. 1 and Fig. 2). Although HepG2 cells were more sensitive to beta-Lp 
cytotoxicity, B16–F10 cells expressing very low NQO1 activity were also killed by beta-Lp, 
especially at 10 μM. Hence, in cancer cells expressing low NQO1 activity beta-Lp still could 
undergo redox activation, catalyzed by METC in addition to NQO1, to produce ROS that 
contributed to cancer cell killing. These results may provide novel insights into the molecular 
and biochemical mechanisms of beta-Lp redox activation in cancer cells to produce ROS that 
contribute to cancer cell death. 
 
Fig. 6. HepG2 cells expressing high NQO1 are sensitive to beta-lapachone cytotoxicity and 
effect of rotenone on beta-Lp-induced cytotoxicity in B16–F10 cells. Cells were seeded on 24-
well plates at a density of 2 × 105/well. 24 h later, the cells were treated with the indicated 
concentrations of beta-lapachone in DMEM containing 0.5% FBS for another 24 h followed by 
morphological examination (panel A) and MTT assay (panel B). Panel C: the cells were treated 
with 10 μM beta-lapachone in the presence or absence of rotenone (10 μM) in DMEM 
containing 0.5% FBS for 24 h followed by MTT assay. *, p < 0.05 versus control; #, p < 0.05 
versus beta-Lp alone (panel D). 
The differential roles of cancer cell mitochondria and NQO1 in beta-Lp redox activation reported 
in this study may significantly contribute to our understanding of how cancer cells are selectively 
killed by beta-Lp. In this context, future work needs to focus on investigating the detailed 
molecular and biochemical differences between cancer cells and normal cells with regard to their 
differential capacities to mediate redox activation of beta-Lp to generate ROS for selective 
cancer cell killing. Studies are currently underway in our laboratory to compare the redox 
activation of beta-Lp in human hepatocellular carcinoma HepG2 cells versus in normal human 
hepatocytes. More experiments are also warranted to further delineate the causal roles of ROS, 
METC, and cellular NQO1 (both low and high activities) in beta-Lp-induced cancer cell killing 
as well as in its potential toxicity to normal cells. The mode of cancer cell death (i.e., necrosis, 
apoptosis, or autophagy) caused by beta-Lp also needs to be determined for further identification 
of signaling pathways involved in the execution of the cancer cell death following beta-Lp 
treatment. Since B16–F10 cells used in this study were derived from C57BL/6 mice, 
investigating the impact of both mitochondria- and NQO1-mediated redox activation of beta-Lp 
on melanoma growth and metastasis in C57BL/6 mice would provide conclusive evidence on 
how cancer cells are selectively killed by beta-Lp. 
In summary, this study for the first time demonstrated real-time formation of ROS from cancer 
cell mitochondria- and NQO1-mediated redox activation of beta-Lp in a concentration-dependent 
manner. In addition, in cancer cells, such as melanoma B16–F10 cells that do not express high 
NQO1 activity, METC also plays a critical role in beta-Lp redox activation. In contrast, in cancer 
cells such as hepatocellular carcinoma HepG2 cells expressing extremely high NQO1 activity, 
redox activation of beta-Lp is primarily mediated by NQO1, and METC plays a minor, if any, 
role in the redox activation process. We further showed that both isolated mitochondria and 
purified NQO1 are able to mediate redox activation of beta-Lp to generate ROS. These findings 
provide the evidence suggesting that the differential roles of mitochondria and NQO1 in 
mediating redox activation of beta-Lp to produce ROS appear to significantly impact the cancer 
cell killing activity of this potentially novel anticancer agent. 
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